217 related articles for article (PubMed ID: 35576849)
1. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
Choi S; Cho SI; Ma M; Park S; Pereira S; Aum BJ; Shin S; Paeng K; Yoo D; Jung W; Ock CY; Lee SH; Choi YL; Chung JH; Mok TS; Kim H; Kim S
Eur J Cancer; 2022 Jul; 170():17-26. PubMed ID: 35576849
[TBL] [Abstract][Full Text] [Related]
2. Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer.
Kim H; Kim S; Choi S; Park C; Park S; Pereira S; Ma M; Yoo D; Paeng K; Jung W; Park S; Ock CY; Lee SH; Choi YL; Chung JH
JCO Precis Oncol; 2024 May; 8():e2300556. PubMed ID: 38723233
[TBL] [Abstract][Full Text] [Related]
3. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
Wu J; Liu C; Liu X; Sun W; Li L; Gao N; Zhang Y; Yang X; Zhang J; Wang H; Liu X; Huang X; Zhang Y; Cheng R; Chi K; Mao L; Zhou L; Lin D; Ling S
Mod Pathol; 2022 Mar; 35(3):403-411. PubMed ID: 34518630
[TBL] [Abstract][Full Text] [Related]
4. An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
Lee KS; Choi E; Cho SI; Park S; Ryu J; Puche AV; Ma M; Park J; Jung W; Ro J; Kim S; Park G; Song S; Ock CY; Choe G; Park JH
Histopathology; 2024 Mar; ():. PubMed ID: 38477366
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
De Marchi P; Leal LF; Duval da Silva V; da Silva ECA; Cordeiro de Lima VC; Reis RM
J Clin Pathol; 2021 Nov; 74(11):735-740. PubMed ID: 33589532
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer.
Hondelink LM; Hüyük M; Postmus PE; Smit VTHBM; Blom S; von der Thüsen JH; Cohen D
Histopathology; 2022 Mar; 80(4):635-647. PubMed ID: 34786761
[TBL] [Abstract][Full Text] [Related]
7. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
Park S; Ock CY; Kim H; Pereira S; Park S; Ma M; Choi S; Kim S; Shin S; Aum BJ; Paeng K; Yoo D; Cha H; Park S; Suh KJ; Jung HA; Kim SH; Kim YJ; Sun JM; Chung JH; Ahn JS; Ahn MJ; Lee JS; Park K; Song SY; Bang YJ; Choi YL; Mok TS; Lee SH
J Clin Oncol; 2022 Jun; 40(17):1916-1928. PubMed ID: 35271299
[TBL] [Abstract][Full Text] [Related]
8. Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images.
van Eekelen L; Spronck J; Looijen-Salamon M; Vos S; Munari E; Girolami I; Eccher A; Acs B; Boyaci C; de Souza GS; Demirel-Andishmand M; Meesters LD; Zegers D; van der Woude L; Theelen W; van den Heuvel M; Grünberg K; van Ginneken B; van der Laak J; Ciompi F
Sci Rep; 2024 Mar; 14(1):7136. PubMed ID: 38531958
[TBL] [Abstract][Full Text] [Related]
9. A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score?
Ito H; Yoshizawa A; Terada K; Nakakura A; Rokutan-Kurata M; Sugimoto T; Nishimura K; Nakajima N; Sumiyoshi S; Hamaji M; Menju T; Date H; Morita S; Bise R; Haga H
Mod Pathol; 2024 Apr; 37(6):100485. PubMed ID: 38588885
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of an Artificial Intelligence-Powered Platform for Prostate Cancer Grading and Quantification.
Huang W; Randhawa R; Jain P; Iczkowski KA; Hu R; Hubbard S; Eickhoff J; Basu H; Roy R
JAMA Netw Open; 2021 Nov; 4(11):e2132554. PubMed ID: 34730818
[TBL] [Abstract][Full Text] [Related]
12. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
[TBL] [Abstract][Full Text] [Related]
13. A Review of Artificial Intelligence in Precise Assessment of Programmed Cell Death-ligand 1 and Tumor-infiltrating Lymphocytes in Non-Small Cell Lung Cancer.
Wu J; Lin D
Adv Anat Pathol; 2021 Nov; 28(6):439-445. PubMed ID: 34623343
[TBL] [Abstract][Full Text] [Related]
14. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Assessment in Needle Core Biopsies of Non-Small Cell Lung Cancer: Interpathologist Agreement and Potential Associated Histopathological Features.
Hacihasanoglu E; Bambul Sigirci B; Usul G; Savli TC
Turk Patoloji Derg; 2024; 40(1):37-44. PubMed ID: 37614090
[TBL] [Abstract][Full Text] [Related]
16. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
[TBL] [Abstract][Full Text] [Related]
17. The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.
Butter R; Hondelink LM; van Elswijk L; Blaauwgeers JLG; Bloemena E; Britstra R; Bulkmans N; van Gulik AL; Monkhorst K; de Rooij MJ; Slavujevic-Letic I; Smit VTHBM; Speel EM; Thunnissen E; von der Thüsen JH; Timens W; van de Vijver MJ; Yick DCY; Zwinderman AH; Cohen D; 't Hart NA; Radonic T
Lung Cancer; 2022 Apr; 166():143-149. PubMed ID: 35279453
[TBL] [Abstract][Full Text] [Related]
18. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
20. Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression.
Ligero M; Serna G; El Nahhas OSM; Sansano I; Mauchanski S; Viaplana C; Calderaro J; Toledo RA; Dienstmann R; Vanguri RS; Sauter JL; Sanchez-Vega F; Shah SP; Ramón Y Cajal S; Garralda E; Nuciforo P; Perez-Lopez R; Kather JN
Cancer Res Commun; 2024 Jan; 4(1):92-102. PubMed ID: 38126740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
